IgA nephropathy FDA verdict

Vertex says it's unfazed as an IgAN decision looms in a crowded field

The kidney-disease space is filling up fast, and the FDA verdict is the next thing on the calendar she can't control.

saying 'unfazed' out loud is what you do when everyone can see the competitors. the real bet is that approval plus vertex's launch machinery beats being first into a market that's already elbows-out.

FDA verdict approaching, competitors crowding